Liver Disease Cell Models for Research

Liver diseases, including hepatocellular carcinoma (HCC), cirrhosis, and non-alcoholic fatty liver disease (NAFLD), represent a major global health burden. According to the World Health Organization (WHO), liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide, with approximately 905,677 new cases and 830,180 deaths in 2020. The 5-year survival rate for liver cancer remains low, at around 20% for localized disease but dropping to 3% for distant stages, as reported by the National Cancer Institute (NCI). Key risk factors include chronic hepatitis B and C infections, alcohol abuse, aflatoxin exposure, and metabolic syndrome. The rising incidence of NAFLD and non-alcoholic steatohepatitis (NASH) is driving an increase in liver disease cases globally.

Liver disease, particularly HCC, is an ideal model for mechanistic studies due to its well-characterized subtypes, extensive public datasets (e.g., TCGA, COSMIC), and the urgent need for novel therapeutic targets. The heterogeneity of liver tumors, driven by diverse etiologies and genetic alterations, presents both challenges and opportunities for precision medicine. Gene-edited cell models enable researchers to dissect the functional consequences of specific mutations, validate drug targets, and explore resistance mechanisms. Open questions include the role of tumor microenvironment, immune evasion, and the development of effective combination therapies.

Hepatocellular carcinoma (HCC) arises from the accumulation of genetic and epigenetic alterations that activate oncogenic pathways and inactivate tumor suppressors. Key pathways include:

• • Wnt/β-catenin signaling: Activating mutations in CTNNB1 (encoding β-catenin) are found in ~30% of HCCs, leading to constitutive activation of the pathway and promoting cell proliferation and survival.
• • p53 pathway: TP53 mutations occur in ~30% of HCCs, impairing cell cycle arrest and apoptosis, and are associated with poor prognosis.
• • PI3K/AKT/mTOR pathway: Alterations in PIK3CA, PTEN, and TSC1/TSC2 lead to enhanced cell growth and survival.
• • MAPK pathway: Mutations in RAS and RAF genes, though less frequent, contribute to uncontrolled proliferation.

Data from TCGA and COSMIC databases.

The molecular pathogenesis of liver disease involves complex signaling networks that interact to drive tumorigenesis. Key networks include:

• • Wnt/β-catenin: Activation leads to nuclear accumulation of β-catenin, which drives transcription of target genes such as MYC and CCND1.
• • PI3K/AKT/mTOR: This pathway is frequently activated due to loss of PTEN or activating mutations in PIK3CA, promoting cell survival and metabolism.
• • MAPK/ERK: RAS/RAF/MEK/ERK cascade is often upregulated, contributing to proliferation and metastasis.
• • JAK/STAT: Chronic inflammation and cytokine signaling activate STAT3, which promotes cell survival and immune evasion.
• • Hedgehog: Aberrant activation of the Hedgehog pathway has been implicated in liver fibrosis and HCC.

Organoids derived from patient tumors or pluripotent stem cells offer a more physiologically relevant model, recapitulating the architecture and genetic heterogeneity of the original tumor. They are valuable for drug testing and personalized medicine approaches.

Animal models are essential for studying liver disease in vivo. Common models include:

• • Patient-derived xenografts (PDX): Tumor fragments implanted into immunodeficient mice, preserving the genetic and histologic features of the patient tumor.
• • Genetically engineered mouse models (GEMM): Mice with targeted mutations in genes such as TP53, CTNNB1, or MYC that develop liver tumors, allowing study of tumor initiation and progression.
• • Induced models: Chemical-induced (e.g., diethylnitrosamine) or diet-induced (e.g., high-fat diet) models that mimic human liver disease, particularly NASH and fibrosis.

CRISPR-based gene editing has revolutionized the creation of isogenic cell models for liver disease research. By introducing precise knockouts or knock-ins of disease-relevant genes, researchers can study the functional impact of specific mutations in a controlled genetic background. For example:

• • TP53 knockout cell lines: Generated in HepG2 or Huh7 backgrounds to study the role of p53 loss in tumor suppression and drug resistance.
• • CTNNB1 knock-in cell lines: Introducing activating mutations (e.g., S33Y) into wild-type cell lines to model constitutive Wnt signaling.
• • TERT promoter mutant cell lines: Knock-in of promoter mutations to study telomerase reactivation.

These gene-edited models are commercially available from various sources, ensuring sequence verification and quality control, and accelerate research by providing consistent and reproducible tools. They are essential for functional genomics, drug screening, and target validation.

Gene-edited cell lines are powerful tools for functional genomics, allowing researchers to determine the role of specific genes in liver disease. For example:

• • Knockout screens: CRISPR knockout libraries can be used to identify genes essential for cell survival or proliferation in liver cancer cells.
• • Knock-in models: Introducing disease-associated mutations into isogenic cell lines enables the study of mutation-specific effects on signaling pathways and drug sensitivity.
• • Reporter lines: Gene-edited cell lines with fluorescent or luminescent reporters (e.g., GFP under a target gene promoter) allow real-time monitoring of gene expression.

Isogenic cell line pairs (wild-type vs. gene-edited) are invaluable for drug screening and resistance studies. For example:

• • Screening: High-throughput screening of compound libraries against isogenic pairs can identify drugs that selectively kill mutant cells, providing leads for targeted therapy.
• • Resistance: By exposing gene-edited cells to increasing concentrations of a drug, researchers can generate resistant clones and identify mechanisms of resistance, such as secondary mutations or pathway reactivation.

CRISPR-based synthetic lethality screens can identify genes that are essential only in the context of a specific mutation, revealing potential therapeutic targets and biomarkers. For example, in TP53-mutant liver cancer cells, knocking out certain genes may lead to cell death, while wild-type cells remain viable. These synthetic lethal interactions can be exploited for targeted therapy and serve as biomarkers for patient stratification.